home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc. From 05/08/24

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating ...
CLRB - Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024

FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its fina...

CLRB - Radiopharma stocks higher as sector welcomes the latest M&A deal

2024-05-02 14:31:50 ET More on Novartis, Novartis AG, etc. Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis AG 2024 Q1 - Results - Earnings Call Presentation Novartis to b...

CLRB - Expected US Company Earnings on Thursday, May 2nd, 2024

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
CLRB - Outperform Recommendation Issued On CLRB By Oppenheimer

2024-03-28 09:15:05 ET Oppenheimer analyst issues OUTPERFORM recommendation for CLRB on March 28, 2024 07:33AM ET. The previous analyst recommendation was Outperform. CLRB was trading at $3.635 at issue of the analyst recommendation. Historical Analyst Recommendations ...

CLRB - Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

2024-03-27 12:27:02 ET Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Conference Call March 27, 2024, 08:30 AM ET Company Participants Jim Caruso - President and CEO Andrei Shustov - SVP, Medical Jarrod Longcor - COO Shane Lea - Chief Commercial Officer ...

CLRB - Expected US Company Earnings on Wednesday, March 27th, 2024

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
CLRB - Cellectar Biosciences GAAP EPS of -$3.11 misses by $0.28

2024-03-27 06:47:52 ET More on Cellectar Biosciences Cellectar Biosciences: A Shoestring Opportunity You're About To Miss Cellectar stock climbs 8% on results for CNS malignancy therapy Cellectar Biosciences gains on pivotal data for radiotherapy Seeking Alph...

CLRB - Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ende...

CLRB - Cellectar Biosciences FY 2023 Earnings Preview

2024-03-26 13:55:51 ET More on Cellectar Biosciences Cellectar Biosciences: A Shoestring Opportunity You're About To Miss Cellectar stock climbs 8% on results for CNS malignancy therapy Cellectar Biosciences gains on pivotal data for radiotherapy Seeking Alph...
Previous 10 Next 10